Cognoptix Closes $15M Series D Financing

cognoptixCognoptix, an Acton, MA-based emerging medical device company, closed the first tranche of a $15m Series D round of financing.

The round was co-led by new investor Alopexx and existing investor Inventages Venture Capital, with participation from original investor Launchpad Venture Group.

The company intends to use the funds to complete the clinical development of its eye test.

Led by Paul Hartung, President and CEO, Cognoptix focuses on developing and commercializing SAPPHIRE II, which is an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD).




Join the discussion